Accessibility Menu
Tevogen logo

Tevogen(NASDAQ) TVGN

Market Cap$41.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-99%
5 YearN/A
1 Year-86%
1 Month+57%
$6.74
+5.81%
+0.37Today
Tevogen last closing stock price
MetricPriceDate
Last closeUSD 6.372026-08-20
Tevogen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.04%USD 6.572026-08-13
1 month+56.9%USD 4.062026-07-21
3 month-33.71%USD 9.612026-05-22
Year to date-61.52%USD 16.562025-12-31
1 year-86.14%USD 45.962025-08-20
3 year-98.81%USD 536.002023-08-16
Since inception-98.72%USD 496.842022-01-05

Tevogen Financials at a Glance

Market Cap

$41.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$21.61M

EPS (TTM)

-$5.83

P/E Ratio

-1.09

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.74

Volume

5,452.623

Open

$6.23

Previous Close

$6.37

Daily Range

$6.23 - $6.87

52-Week Range

$3.64 - $49.50

Estimated Earnings Date

Nov 13, 2026

TVGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tevogen

Tevogen develops cell-based therapies for serious diseases like COVID-19 and cancer. Its products aim to help patients with limited treatment options. The company focuses on making these therapies available quickly and efficiently.

Lab Coats and Life Savers: Products and Services

  • Precision T cell therapies: Off-the-shelf treatments using immune cells to target viruses and cancers; 0% of revenue (no sales yet).
  • TVGN 489: Lead product for high-risk COVID-19 and long COVID patients; 0% of revenue.
  • TVGN 920/960: Products in development for cancers linked to human papillomavirus (HPV); 0% of revenue.
  • TVGN 116/601/930: Pipeline therapies for hepatitis B, multiple sclerosis, and certain lymphomas; 0% of revenue.
  • Tevogen.AI: Early-stage artificial intelligence project to speed up drug development; 0% of revenue.

Growth Spurts and Science Sprints: Growth and Expansion

  • Completed Phase 1 trial for TVGN 489 in high-risk COVID-19 patients in 2023.
  • Expanded ExacTcell platform to new disease areas in 2024 and 2025.
  • Leased expanded headquarters in Warren, NJ in 2025; Philadelphia R&D facility lease expired in 2025.
  • Signed letter of intent in 2026 to acquire over 50% of a clinical research organization.
  • Formed collaborations with AI and technology companies in 2025 to support drug development.

Why Tevogen Is a Bit Different

Tevogen uses a process called ExacTcell to create cell therapies from healthy donors, aiming for quick and scalable production. Its therapies are designed to work for many patients without genetic modification. The company integrates artificial intelligence to improve research and development speed.

Five Things You Need to Know

  • No revenue reported in 2023, 2024, or 2025.
  • Net loss was $26.3 million in 2025, compared to $13.7 million in 2024.
  • Cash was $0.6 million at December 31, 2025, with $12.6 million in liabilities.
  • Operating expenses were $26.1 million in 2025, compared to $53.6 million in 2024.
  • Company relies on external funding and has not yet launched commercial products.

Bottom Line

Tevogen is an early-stage biotech focused on cell therapies for hard-to-treat diseases. The company is investing in research and infrastructure but has yet to generate revenue.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

18

CEO

Ryan Saadi, MD

Website

www.tevogen.com

Headquarters

Warren, NJ 07059, US

TVGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

248.50%

Return on Capital

N/A

Return on Assets

-457.14%

Earnings Yield

-91.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$41.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.51M

Volume

5.45K

Avg. Volume

22.57K

Financials (TTM)

Gross Profit

-$204.98K

Operating Income

-$21.40M

EBITDA

-$20.95M

Operating Cash Flow

-$11.57M

Capital Expenditure

-$64.43K

Free Cash Flow

-$11.63M

Cash & ST Invst.

$1.08M

Total Debt

$3.04M

Tevogen Performance Analysis

Tevogen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tevogen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Tevogen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.60N/A
20232023-12-31USD -122.17N/A
20242024-12-31USD -3.50-97.1%
20252025-12-31USD -8.08130.7%
Tevogen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.0%
Q42025-12-3120.0%
Q12026-03-31-34.2%
Q22026-06-305.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$60.14K

N/A

Gross Margin

0.00%

N/A

Market Cap

$41.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.30M

N/A

Employees

18

N/A

Net Income

-$5.76M

-4.7%

EBITDA

-$5.60M

-2.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.08M

+57.9%

Total Debt

$3.04M

-59.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.06M

-80.9%

Short Term Debt

$1.98M

+0.0%

Return on Assets

-4.57%

N/A

Return on Invested Capital

15.04%

N/A

Free Cash Flow

-$3.01M

+5.8%

Operating Cash Flow

-$3.01M

+5.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TILInstil Bio, Inc.
$7.59+2.15%
CLNNClene Inc.
$4.33-1.03%
ATOSAtossa Therapeutics, Inc.
$2.57-0.97%
ONCYOncolytics Biotech Inc.
$0.82+2.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.69+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.42+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.83+0.11%
MARAMara Holdings
$11.40+0.02%

Questions About TVGN

What is the current price of Tevogen?

Tevogen is trading at $6.85 per share.

What is the 52-week range for Tevogen?

Over the past 52 weeks, Tevogen has traded between $3.64 and $49.50.

How much debt does Tevogen have?

As of the most recent reporting period, Tevogen reported total debt of $9.44M.

How much cash does Tevogen have on hand?

Tevogen reported $1.08M in cash and cash equivalents in its most recent financial results.

What is Tevogen’s dividend yield?

Tevogen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services